Tigulixostat

Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC50 values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia[1][2][3][4].

Product Specifications

CAS Number

[1287766-55-5]

Product Name Alternative

LC350189

UNSPSC

12352005

Target

Xanthine Oxidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/tigulixostat.html

Purity

99.18

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N#CC1=CN(C(C)C)C2=C1C=C(N3N=CC(C(O)=O)=C3)C=C2

Molecular Formula

C16H14N4O2

Molecular Weight

294.31

References & Citations

[1]Seonghae Yoon, et al. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49. |[2]Terkeltaub R, et al. Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. Arthritis Rheumatol. 2023 Jul;75 (7) :1275-1284.|[3]Xue L, et al. Tigulixostat Alleviates Hyperuricemic Nephropathy by Promoting M2 Macrophage Polarization. J Inflamm Res. 2025 Jan 3;18:17-30.|[4]Kumar A, et al. AB0101 PRECLINICAL IN VITRO AND IN VIVO EFFICACY STUDIES OF TIGULIXOSTAT, A SELECTIVE NON-PURINE XANTHINE OXIDASE INHIBITOR. Annals of the Rheumatic Diseases, 2024, 83: 1284.